Page last updated: 2024-11-04

flutoprazepam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3400
CHEMBL ID2106743
CHEBI ID31629
SCHEMBL ID124578
MeSH IDM0093205

Synonyms (37)

Synonym
kb-509
flutoprazepam
restas
c19h16clfn2o
id-1937
flutoprazepamum [inn-latin]
7-chloro-1-cyclopropylmethyl-1,3-dihydro-5-(2-fluorophenyl)-2h-1,4-benzodiazepin-2-one
2h-1,4-benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-1,3-dihydro-
flutoprazepam [inn:jan]
2h-1,4-benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-5-(o-fluorophenyl)-1,3-dihydro-
brn 0898682
7-chloro-1-(cyclopropylmethyl)-5-(o-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one
restar
flutoprazepam (jp17/inn)
D01279
restas (tn)
25967-29-7
7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-3h-1,4-benzodiazepin-2-one
CHEMBL2106743
AKOS016013927
unii-2ghy1101mm
2ghy1101mm ,
flutoprazepamum
SCHEMBL124578
flutoprazepam [mi]
flutoprazepam [who-dd]
flutoprazepam [inn]
flutoprazepam [mart.]
flutoprazepam [jan]
7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-1h-benzo[e][1,4]diazepin-2(3h)-one
DTXSID20180631
CHEBI:31629
(e)-7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-1h-benzo[e][1,4]diazepin-2(3h)-one
Q5462983
methyl5,6-dichloro-3-indoleacetate
7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-1,3-dihydro-2h-benzo[e][1,4]diazepin-2-one
7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-2,3-dihydro-1h-1,4-benzodiazepin-2-one

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" This metabolite appeared in serum rapidly (within 2 h), reached a peak between 2 and 12 h and declined slowly, with an elimination half-life of about 90 h on average."( Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects.
Barzaghi, N; Leone, L; Monteleone, M; Perucca, E; Tomasini, G,
)
0.45
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (83.33)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.81 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index40.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]